1
|
Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, Yang D, Meglan A, Ribeiro J, Blandin J, Phan N, Bell GW, Hata AN, Weiskopf K. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. J Clin Invest 2024; 134:e169315. [PMID: 38483480 PMCID: PMC11060739 DOI: 10.1172/jci169315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 03/12/2024] [Indexed: 03/26/2024] Open
Abstract
Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown, and ongoing studies suggest they may be most effective when used in combination with other anticancer agents. Here, we developed an unbiased, high-throughput screening platform to identify drugs that render lung cancer cells more vulnerable to macrophage attack, and we found that therapeutic synergy exists between genotype-directed therapies and anti-CD47 antibodies. In validation studies, we found that the combination of genotype-directed therapies and CD47 blockade elicited robust phagocytosis and eliminated persister cells in vitro and maximized antitumor responses in vivo. Importantly, these findings broadly applied to lung cancers with various RTK/MAPK pathway alterations - including EGFR mutations, ALK fusions, or KRASG12C mutations. We observed downregulation of β2-microglobulin and CD73 as molecular mechanisms contributing to enhanced sensitivity to macrophage attack. Our findings demonstrate that dual inhibition of the RTK/MAPK pathway and the CD47/SIRPa axis is a promising immunotherapeutic strategy. Our study provides strong rationale for testing this therapeutic combination in patients with lung cancers bearing driver mutations.
Collapse
Affiliation(s)
- Kyle Vaccaro
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Juliet Allen
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Troy W. Whitfield
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Asaf Maoz
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Sarah Reeves
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
| | - José Velarde
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Dian Yang
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Anna Meglan
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Juliano Ribeiro
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Jasmine Blandin
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Nicole Phan
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
| | - George W. Bell
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
| | - Aaron N. Hata
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
- Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Kipp Weiskopf
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| |
Collapse
|
2
|
Soyez F, Chalumeau F, Blandin J, Vidilles JL, Carrie AS, D’Ortho M. Étude de la prévalence du SAOS chez des rugbymen professionnels. Neurophysiol Clin 2013. [DOI: 10.1016/j.neucli.2013.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|